In the pharmaceutical industry, packaging is far more than a visual wrapper — it is a functional system that protects product stability, safety, and efficacy throughout shelf life. When packaging materials fail, the consequences can range from stability failures to global product recalls. Regulatory bodies such as USFDA and EMA expect companies to rigorously assess and monitor packaging performance during product development and beyond.
Types of Packaging Material Failures
Common failure modes of packaging materials in stability programs include:
- ❌ Delamination: Separation of laminate layers, especially in foil-based pouches
- ❌ Pinhole or Seal Breach: Resulting in loss of moisture or oxygen barrier
- ❌ High OTR or WVTR: Barrier performance degrades over time or under stress
- ❌ Leachables Migration: Interaction of inks, adhesives, or plastics with the drug product
- ❌ Incompatibility: Between the primary container and the formulation (e.g., sorption, adsorption)
Stability Impact of Packaging Failures
Failure of packaging to maintain critical barriers—such as to moisture, oxygen, or light—can trigger a cascade of stability issues:
- Increased impurity formation due to oxidative stress
- Assay degradation caused by hydrolysis
- Color change and tablet softening in humid environments
- Decreased dissolution performance for film-coated tablets
- Microbial growth in sterile or semi-solid formulations
These problems can manifest during stability studies or post-marketing and lead to OOS results, recalls, or warning letters.
Case Example: Blister Pack Failure in Accelerated Stability
In one documented case, a company used PVC/PE blisters for a moisture-sensitive API. At the 6-month accelerated time point (40°C/75% RH), the assay dropped below 90% and impurities rose above threshold. Investigation revealed inadequate WVTR protection. Upon switching to PVDC-coated PVC, the product passed all subsequent studies. This underscores the role of correct material choice.
Testing Protocols to Detect Material Failures
Pharma companies must implement comprehensive tests for packaging performance, including:
- Seal Integrity: Vacuum decay or dye ingress testing
- Moisture Vapor Transmission Rate (MVTR): ASTM F1249 or USP
- Oxygen Transmission Rate (OTR): ASTM D3985
- Delamination Strength: Measured with peel or tensile tests
- Extractables and Leachables: As per USP and
Regulatory Expectations for Packaging Performance
Regulators expect firms to include data on packaging validation and failure analysis in Module 3.2.P.7 of the CTD:
- ☑ Justification for packaging selection based on product risk
- ☑ Comparative barrier data for alternative packaging
- ☑ Results of packaging qualification studies
- ☑ Risk management outcomes using ICH Q9 principles
Refer to equipment qualification practices when validating packaging lines for sealing consistency.
Root Cause Investigation Framework for Packaging Failures
When failures arise, use structured tools to determine the origin:
- Ishikawa Diagrams: For mapping material, machine, method, and personnel factors
- FMEA: To prioritize risk based on severity and occurrence
- Historical Trending: For identifying patterns in vendor or batch failures
CAPAs should address both immediate causes (e.g., seal temperature) and systemic issues (e.g., inadequate material qualification).
Checklist: Packaging Failure Prevention in Stability Studies
- ☑ Are all packaging components fully qualified and documented?
- ☑ Is WVTR/OTR data consistent with product stability needs?
- ☑ Have integrity tests been conducted across worst-case conditions?
- ☑ Are extractables/leachables studies included in dossier?
- ☑ Are packaging deviations investigated with proper root cause tools?
- ☑ Is there a cross-functional review process for packaging changes?
Conclusion
Packaging material failures can significantly compromise drug product stability and patient safety. Pharma professionals must integrate robust qualification, monitoring, and investigation procedures to ensure packaging consistently protects the drug throughout its shelf life. Regulatory authorities emphasize packaging risk management as a core quality expectation—and failure to meet these can result in serious compliance consequences.
References:
- ICH Q1A(R2): Stability Testing Guidelines
- USP : Containers – Performance Testing
- USP /: Extractables and Leachables
- FDA Guidance for Industry: Container Closure Systems
- EMA Packaging Guidance for Medicinal Products